^
Association details:
| Biomarker: | HRD |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients
Published date:
04/12/2022
Excerpt:
In our center, we found that two HRD-L HNSCC patients presented with an inflamed tumor microenvironment and had a good response to PD-1 therapy. Interestingly, the higher HRD score was 31 and was a non-responder to ICI treatment....HRD-H is associated with poor outcome in HNSCC patients. Those patients may benefit from PARPi treatment rather than ICIs treatment for its non-inflamed tumor microenvironment.
DOI:
10.1016/j.oraloncology.2022.105860
